Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$162.03
pos +1.50
+0.92%
Today's Range: 161.00 - 163.16 | AMGN Avg Daily Volume: 3,508,600
Last Update: 03/27/15 - 11:56 AM EDT
Volume: 709,740
YTD Performance: 0.79%
Open: $161.26
Previous Close: $160.55
52 Week Range: $108.20 - $173.14
Oustanding Shares: 758,861,306
Market Cap: 121,888,302,970
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 2 2 2 2
Hold 8 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.09 2.17 2.17 2.11
Latest Dividend: 0.79
Latest Dividend Yield: 1.97%
Dividend Ex-Date: 05/12/15
Price Earnings Ratio: 23.97
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
23.97 24.00 27.33
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.78% 33.67% 137.78%
GROWTH 12 Mo 3 Yr CAGR
Revenue 7.40 0.29 0.09
Net Income 1.50 0.40 0.12
EPS 0.90 0.67 0.18
Earnings for AMGN:
EBITDA 8.74B
Revenue 20.06B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $2.09 $2.38 $9.36 $10.53
Number of Analysts 10 9 13 11
High Estimate $2.40 $2.45 $9.75 $11.23
Low Estimate $1.95 $2.29 $9.21 $10.08
Prior Year $1.86 $2.37 $8.68 $9.36
Growth Rate (Year over Year) 12.20% 0.61% 7.81% 12.52%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Gary Berman

 | Mar 23, 2015 | 9:59 AM EDT

The stock recently generated a long-term overbought signal.

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

By

Jim Cramer

 | Mar 21, 2015 | 2:30 PM EDT

Own them, or take something off the table?

By

Jim Cramer

 | Mar 19, 2015 | 6:52 PM EDT

Market backtracks on skepticism over biotechs.

By

Jim Cramer

 | Mar 18, 2015 | 7:39 AM EDT

A Fed-related dip may be your only hope to get in lower.

By

Bret Jensen

 | Mar 17, 2015 | 11:00 AM EDT

Amgen and Gilead shine in one of the market's best-performing sectors.

By

Jim Cramer

 | Mar 16, 2015 | 11:57 AM EDT

It shouldn't be possible, but it never seems too late to get in.

updateCowen Healthcare Conf.

Mar 2, 2015 | 7:50 AM EST

Cowen Health Care Conference (Day 1 of 3) - 03/02/15 - 03/04/15 Boston, M

By

TheStreet

 | Feb 4, 2015 | 1:45 PM EST

The debate raging among investors about hepatitis C revenue declines.

By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?
I agree - how can you not question the valuation after the huge move in KRFT shares. My th...
CME is attempting to hold a key near term support area following a mid week breakdown....
Fantastic and insightful piece by @adamlashinsky on #Apple and @tim_cook in the new issue ...
I have loved this $KRFT deal but it has now gotten a little overheated and I am beginning ...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.